By merging components of four different hormones into a single drug, researchers aim to combat obesity while also tackling related conditions such as type 2 diabetes, cancer, and cardiovascular ...

Although Saxenda is the first generic GLP-1 to hit the US market, its sales will likely be overshadowed by next-gen drugs ...

In December 2024, Teva also secured FDA approval for the other liraglutide brand Victoza, indicated for type 2 diabetes.

The FDA has approved the first generic GLP-1 specifically indicated for weight loss, according to a press release from Teva Pharmaceuticals. As Healio previously reported, Teva Pharmaceuticals ...

"Ozempic face." Five years ago, if you'd heard those words you would probably think it referred to an alien species.

Parsippany: Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd., has announced the FDA approval and U.S. launch of a generic version of Saxenda ...

The FDA approved the first-ever generic form of a GLP-1 receptor agonist specifically indicated for weight loss, Teva Pharmaceuticals announced Thursday. The generic form of liraglutide (Saxenda) is ...

GoodRx reports that HSA and FSA can cover weight-loss expenses if prescribed for medical conditions, requiring a letter of ...

The drug, which is prescribed to around 90% of people in the UK using weight-loss injections, will see the cost of its ...

Teva is releasing a generic version of Novo Nordisk’s Saxenda, a liraglutide injection. Liraglutide injection is indicated for adults with obesity or overweight who also have weight related medical ...

Teva Pharmaceuticals has received FDA approval and has launched a generic version of Saxenda (liraglutide), which is approved to treat adults and adolescents 12 to 17 years of age who are obese or ...

Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the ...